awmsg logo



vildagliptin (Galvus®)


Reference No. 1393

Publication date:
25/10/2012


Last review date:
30/08/2016

Appraisal information

vildagliptin (Galvus®) 50 mg tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Endocrine system
NMG meeting date: 10/07/2012
AWMSG meeting date: 12/09/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3012
Ministerial ratification: 25/10/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Vildagliptin (Galvus®) 50 mg tablets are recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download